

# Wearables and Application Solutions for Parkinson's Disease: An Overview



Joseph P. Giuffrida, PhD  
President & Principal Investigator

---

Parkinson's Disease: Challenges and Opportunities

5 min

---

Wearable Technology Space & Big Data

---

---

Wearables Road Map

10 min

---

Clinical Validation of Wearables

---

Targeted Applications within Targeted Applications

---

---

Closing the Clinical Workflow

10 min

---

Closing the Business Case

---

Closing the Patient Perspective

---

---

Questions

5 min

# Parkinson's Disease: Challenges and Opportunities

# Parkinson's is Very Difficult

## SYMPTOMS

Tremor

Dyskinesias

Bradykinesia

Rigidity

Gait

Non-Motor et al.

## TREATMENTS

Levodopa

Rasagiline

Duodopa

DBS

Exercise

Neuroprotection?

## DEMOGRAPHICS

Over 60

Growing Incidence


Neurodegeneration

Medicare

VA

Access to Care

# Advanced Parkinson's



# Wearable Technology Space & Big Data



# Intel, Michael J. Fox and Big Data: Fighting Parkinson's Disease

By Virginia Backaitis | Aug 13, 2014

 Follow

908 followers

**Featured Webinar: Why You Can't Afford Your Homegrown CMS**



You've been there. In the doctor's office that is. You're not feeling well and you want to tell the doc all about it, but he wants to ask you questions like: How would you rate the pain on a scale of 1 to 10? When did this start? How long does it last? How would you rate your sleep 1 to 10?

You answer the questions with what is, at best, a guess. And the doctor makes assessments based upon your answers. But is what he calls an "8" the same thing you call an 8? And what does "sleeping well" actually mean? (And, yes, we know there's information like heart rate, blood pressure, lab work data to consider, but we're putting that aside for the moment.)


Now forget about yourself and think of a Parkinson's patient. Michael J. Fox or Intel's Andy Grove may be the ones we "know" best, unless there's someone in our personal lives who has been affected. Their doctors probably include some




# Apple ResearchKit Turns iPhones Into Medical Diagnostic Devices

Posted Mar 9, 2015 by [Josh Constine \(@joshconstine\)](#)

3,737  
SHARES



Medical research is plagued by small sample sizes and inconsistent data



## Parkinson mPower study app

By Sage Bionetworks, a Not-For-Profit Research Organization

Open iTunes to buy and download apps.

[View More by This Developer](#)



[View in iTunes](#)

Free  
Category: Medical  
Released: Mar 09, 2015  
Version: 1.0  
Size: 69.6 MB  
Language: English  
Seller: Sage Bionetworks, a Not-For-Profit Research Organization  
© 2015, Sage Bionetworks  
[You must be at least 17 years old to download this app.](#)  
Infrequent/Mild Alcohol, Tobacco, or Drug Use or References  
Frequent/Intense Medical/Treatment Information


### Description

How can we together better manage the symptoms of Parkinson disease?

Living with Parkinson disease means coping with symptoms that change daily. Yet these daily changes are not


[Sage Bionetworks, a Not-For-Profit Research Organization Web Site](#) [Parkinson mPower study app Support](#) ...More

### iPhone Screenshot





Turns out,  
you can  
measure  
desire.





Done



# Dangerous

BIG DATA



Get it on  
**iTunes**

**SHARE**



**RAM**  
RAM 1500



**EXPLORE  
DETAILS**

**LISTEN FREE**



**rdio**

**LISTEN NOW**



**beatsMUSIC**

**LYRICS**

Peepin' through  
the floor, it's like  
they know  
It's like they  
know I'm

# Can Parkinson's Wearables Learn from MS?

## Biogen idec explores use of wearables to track MS patient activity

March 10, 2015 8:29 pm by [Stephanie Baum](#) | 10 Comments



9



86



50



27

As part of an effort by [Biogen idec](#) to explore ways to use wearables with MS patients to help physicians quantify patient activity, it recently completed a study of 250 patients in collaboration with [PatientsLikeMe](#), Naomi Fried, vice president of medial information and innovation at Biogen, referenced the study as part of a keynote presentation on digital health at the MidAmerica Healthcare Venture Forum in Chicago this week.

This is the problem that Biogen idec wants to solve. Impaired mobility affects more than 90 percent of people with MS, but the quantified assessment of their walking ability tends to be limited to clinical settings. Sensors could give physicians a more accurate assessment of the level of activity of these patients if they were willing to wear activity trackers between appointments.

The study of 250 people with MS sought an answer to the questions: Would patients actually use wearables as part of their daily lives and be willing to share that information with physicians?

The initial takeaway from the study is that it needs to use devices with more sophisticated sensors to quantify movement accurately and consistently. "Current technology is not built to provide consistent and validated data in MS. We are early in the process, but hope to have progress in the coming months," according to an emailed statement about the study from Biogen. It also noted that it was encouraged by the "overwhelming positive participation" from MS patients. It took the response as a sign of encouragement as it explores using wearables in the future.

# Big Enough Data



# Agile Development: Systems, Algorithms, and Applications



Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
7:01 AM	4.0	3.5	2.5	2.4	2.2	0.0
7:02 AM	SINEMET (100mg)					
7:32 AM	3.4	3.3	1.7	1.4	1.0	0.0
8:01 AM	3.0	3.0	1.8	1.8	1.2	0.0
8:34 AM	2.9	2.8	1.3	1.2	1.0	0.0
9:00 AM	2.8	2.4	1.2	1.1	1.2	0.0
9:23 AM	2.8	2.6	1.0	1.0	1.0	0.0
10:00 AM	2.6	2.8	1.0	1.0	1.0	0.0
10:33 AM	3.2	3.3	1.5	1.9	1.5	0.0
11:01 AM	3.5	3.5	2.3	2.2	2.0	0.0
11:30 AM	3.7	3.8	2.0	2.0	1.8	0.0
12:00 PM	SINEMET (100mg)					
12:01 PM	3.3	3.8	2.6	2.7	2.0	0.0
12:32 PM	3.2	3.4	1.8	1.9	2.0	0.0
1:08 PM	2.6	3.1	2.0	1.4	1.8	0.0
1:28 PM	2.6	2.9	1.5	1.2	1.7	0.0
2:00 PM	2.7	2.7	1.3	1.0	1.5	0.0
2:32 PM	2.9	2.6	1.0	1.2	1.7	0.0
3:00 PM	3.0	2.9	1.1	1.5	1.3	0.0
3:29 PM	3.3	3.1	1.4	1.7	1.7	0.0
4:02 PM	3.8	3.8	1.6	1.8	1.8	0.0
4:30 PM	3.9	3.8	1.9	1.9	2.0	0.0
5:01 PM	3.9	3.9	2.5	2.4	2.0	0.0
5:15 PM	SINEMET (100mg)					
5:29 PM	3.5	3.6	2.1	2.2	2.0	0.0
6:02 PM	3.3	3.5	2.0	2.1	1.6	0.0
6:30 PM	3.0	2.9	1.9	2.0	1.5	0.0
7:00 PM	2.8	2.5	1.5	1.8	1.3	0.0
	1.5	1.1	0.0			
	1.4	0.9	0.0			
	1.5	1.1	0.0			
	1.6	1.4	0.0			
	1.8	1.8	0.0			
	1.9	2.1	0.0			
	1.7	1.6	0.0			
	0.4	0.4	0.0			

Increase dose by 200mg, Dose interval unchanged

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
6:55 AM	3.9	3.4	2.6	2.5	2.3	0.0
6:57 AM	SINEMET (300mg)					
7:28 AM	2.5	3.0	1.7	1.4	1.0	0.0
7:59 AM	0.5	1.9	1.8	1.5	1.2	1.3
8:30 AM	0.3	0.9	0.3	0.5	1.0	2.9
9:05 AM	0.1	0.5	0.2	0.2	1.2	3.5
9:33 AM	0.3	0.4	0.0	0.0	1.0	3.8
10:02 AM	0.5	0.1	0.5	0.3	1.0	3.7
10:31 AM	1.5	2.0	1.0	0.5	1.5	2.9
10:58 AM	3.0	3.1	2.3	2.2	2.0	0.0
11:35 AM	3.5	3.4	2.0	2.0	1.8	0.0
11:50 PM	SINEMET (300mg)					
11:56 PM	1.1	2.7	2.3	2.2	2.0	0.0
12:30 PM	0.2	2.0	1.8	1.9	2.0	3.0
1:04 PM	0.1	1.4	2.0	1.4	1.8	3.3
1:38 PM	0.0	1.1	0.8	0.9	1.7	3.5
2:02 PM	0.0	1.0	0.6	1.0	1.5	3.8
2:30 PM	0.2	1.0	1.0	1.2	1.7	2.4
3:07 PM	0.4	0.7	1.1	1.5	1.3	1.1
3:33 PM	0.5	1.3	1.4	1.7	1.7	0.0
4:03 PM	2.0	1.5	1.6	1.8	1.8	0.0
4:28 PM	3.5	2.0	1.9	1.9	2.0	0.0
5:00 PM	3.8	2.2	2.1	2.1	2.0	0.0
5:05 PM	SINEMET (300mg)					
5:39 PM	3.5	2.2	2.1	2.2	2.0	0.0
6:03 PM	2.3	2.0	2.0	2.1	1.6	0.0
6:29 PM	1.7	1.3	1.9	2.0	1.5	0.5
7:05 PM	0.8	1.1	1.5	1.8	1.3	1.0
7:36 PM	0.6	0.8	1.2	1.5	1.1	2.3
8:01 PM	0.3	0.6	1.0	1.4	0.9	3.8
8:28 PM	0.2	1.0	1.2	1.5	1.1	3.7
9:00 PM	0.3	1.1	1.3	1.6	1.4	1.3
9:34 PM	0.3	2.0	1.6	1.8	1.8	0.5
9:59 PM	2.8	2.3	2.0	1.9	2.1	0.0
Mean	1.3	1.6	1.4	1.5	1.6	1.6
Fluctuation	1.3	0.9	0.7	0.6	0.4	1.5

Decrease dose by 100mg, Decrease dose interval by 2 hours

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
7:00 AM	3.5	3.2	2.7	2.5	2.4	0.0
7:01 AM	SINEMET (200mg)					
7:31 AM	2.0	2.1	1.9	2.1	2.2	0.0
8:00 AM	0.6	0.7	0.3	0.5	1.0	0.0
8:33 AM	0.3	0.5	0.2	0.2	1.2	0.0
8:59 AM	0.2	0.2	0.0	0.0	1.0	0.0
9:22 AM	0.2	0.0	0.5	0.3	1.0	0.0
9:59 AM	1.1	1.5	1.0	0.5	1.5	0.0
10:32 AM	SINEMET (200mg)					
11:00 AM	1.2	1.3	1.5	1.4	1.5	0.0
11:29 AM	0.3	0.3	0.5	0.6	2.1	0.0
11:59 AM	0.2	0.2	0.3	0.3	1.0	0.0
12:00 PM	0.1	0.0	0.4	0.1	2.3	0.0
12:31 PM	0.2	0.6	0.6	0.1	2.1	0.0
1:07 PM	1.2	1.6	1.7	1.6	1.7	0.0
1:27 PM	SINEMET (200mg)					
1:59 PM	1.0	0.8	1.0	0.9	1.0	0.0
2:31 PM	0.3	0.7	0.3	0.8	0.9	0.0
2:59 PM	0.2	0.5	0.2	0.5	0.9	0.0
3:28 PM	0.0	0.3	0.2	0.8	0.9	0.0
4:01 PM	0.5	0.8	0.9	1.6	1.7	0.0
4:29 PM	1.3	1.7	1.6	2.1	2.1	0.0
5:00 PM	SINEMET (200mg)					
5:14 PM	1.0	1.5	1.0	0.9	1.0	0.0
5:28 PM	0.3	0.6	0.3	0.8	2.4	0.0
6:01 PM	0.2	0.3	0.2	0.5	2.0	0.0
6:29 PM	0.0	0.0	0.2	0.8	1.7	0.0
6:59 PM	0.5	0.2	0.9	1.6	1.2	0.0
7:32 PM	1.3	0.9	1.6	2.1	1.0	0.0
8:03 PM	SINEMET (200mg)					
8:29 PM	0.8	0.6	0.5	0.7	0.5	0.0
9:01 PM	0.0	0.2	0.2	1.1	0.9	0.0
9:32 PM	0.0	0.1	0.9	1.6	1.3	0.0
9:55 PM	0.5	0.6	1.9	2.0	1.9	0.0
Mean	0.7	0.8	0.8	1.0	1.5	0.0
Fluctuation	0.7	0.7	0.7	0.7	0.5	0.0

Amplitude Configuration  
0 mA A

Stim Settings


Kinesia Tasks  
Postural Tremor ✓  
Rest Tremor  
Finger Taps

Manual Tasks  
Gait  
Rigidity

Side Effects  
None

End Session

Back



UPDATE MAP

Set Threshold

Assign Final Settings

Kinesia Tasks  
Postural Tremor  
Rest Tremor  
Bradykinesia  
Finger Taps  
Speed  
Amplitude  
Rhythm

Manual Tasks

# Clinical Validation and Publications

## NIH Funding

Over \$25 Million in SBIR Funding

---

- National Institute of Health, US
- State of Ohio Commercialization Programs

## Collaborators

Over 30 Collaborating Institutions

---

- Clinical Testing
- Research Collaboration
- Commercialization Partners
- Controlled Database with over 1,000 Patients

## Publications

Over 75 Peer-Reviewed & Presentations

---

- Tremor, Bradykinesia & Dyskinesia Assessment
- Parkinson's Telemedicine
- Deep Brain Stimulation Programming
- Clinical Trials

# Quality and Regulatory

## FDA Clearance to Market

- 510k Clearance to Market
  - Intended Use
    - Kinesia is intended to monitor physical motion and muscle activity to quantify kinematics of movement disorder symptoms such as tremor and assess activity in any instance where quantifiable analysis of motion and muscle activity is desired.

## ISO, CE Mark, Health Canada, and TGA

- ISO 13485:2003
- European Medical Device Directive 93/42/EEC
- Canadian Medical Device Conformity Assessment System
- EMERGO EUROPE: Authorized Agent



## Standards and Testing

- Tested to IEC 60601 Standards
- Complies with FCC Part 15 Rules
- HIPAA Compliant



# Wearables Roadmap

## Context



## Environment



Hello My Name Is...

**Would I Use Wearables?**

**I Want My Doctor to See...**

# A Road Map for Parkinson's Wearables



What Symptoms are You Trying to Measure?

Detection or Severity?

Are Symptoms Voluntary or Involuntary?

Context of Daily Life?

Patient Environment and Confounding Factors?

# Clinical Validation of Wearables

# Clinical Validation Workflow

Start with Controlled Environment

Include Broad Range of Severities

Compare Versus Traditional Gold Standard (Video)


Demonstrate Correlations, Sensitivity, and Test-Retest Reliability

Move to Unconstrained Environment and Tasks That Mask or Mimic Symptoms




# Discrete Tremor Assessment


## Rest Tremor



## Postural Tremor



## Kinetic Tremor




Published



Giuffrida, J. P., Riley, D, Maddux, B, and Heldman, D.A. Clinically deployable Kinesia technology for automated tremor assessment. *Movement Disorders* 24 (5): 723-730, 2009.

# Discrete Bradykinesia Assessment



## Objective Quantification



Kinematic features are highly correlated to clinician MBRS scores

## Published



Heldman, DA; Giuffrida, JP; Chen, R; Payne, M; Mazzella, F; Duker, AP; Sahay, A; Kim, SJ; Revilla, FJ; Espay, AJ. The Modified Bradykinesia Rating Scale for Parkinson's disease: Reliability and Comparison with Kinematic Measures. *Movement Disorders*. 2011.

# Discrete Dyskinesia Assessment









Published



Mera, TO, Burack, MA, and Giuffrida, JP. "Quantitative Assessment of Levodopa Induced Dyskinesia Using Automated Motion Sensing Technology", IEEE-EMBS Proceedings 2012.

# Discrete Gait and Balance Assessment




## Recently Published




TO. Mera, DE. Filipkowski, DE. Riley, Christina M. Whitney, Benjamin L. Walter, Steven A. Gunzler, Joseph P. Giuffrida, "Quantitative analysis of gait and balance response to deep brain stimulation in Parkinson's disease" [Gait & Posture](#) - 07 December 2012

# Test-Retest Reliability: Intra Class Correlations



## Sensitivity: Minimum Detectable Changes, % of Full Scale






**Targeted Applications**

Targeted Applications

# Objective Sensor



# Mobile App



# Web Portal and Reports

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
6:55 AM	3.0	3.4	2.6	2.5	2.3	0.0
6:57 AM	SINEMET (300mg)					
7:28 AM	2.5	3.0	1.7	1.4	1.0	0.0
7:59 AM	0.5	1.9	1.8	1.5	1.2	1.3
8:30 AM	0.3	0.9	0.3	0.5	1.0	2.9
9:05 AM	0.1	0.5	0.2	0.2	1.2	3.5
9:33 AM	0.3	0.4	0.0	0.0	1.0	3.8
10:02 AM	0.5	0.1	0.5	0.3	1.0	3.7
10:31 AM	1.5	2.0	1.0	0.5	1.5	2.9
10:58 AM	3.0	3.1	2.3	2.2	2.0	0.0
11:35 AM	3.5	3.4	2.0	2.0	1.8	0.0
11:50 PM	SINEMET (300mg)					
11:56 PM	1.1	2.7	2.3	2.2	2.0	0.0
12:30 PM	0.2	2.0	1.8	1.9	2.0	3.0
1:04 PM	0.1	1.4	2.0	1.4	1.8	3.3
1:38 PM	0.0	1.1	0.8	0.9	1.7	3.5
2:02 PM	0.0	1.0	0.6	1.0	1.5	3.6
2:30 PM	0.2	1.0	1.0	1.2	1.7	2.4
3:07 PM	0.4	0.7	1.1	1.5	1.3	1.1
3:33 PM	0.5	1.3	1.4	1.7	1.7	0.0
4:03 PM	2.6	1.5	1.6	1.8	1.8	0.0
4:28 PM	3.5	2.0	1.9	1.9	2.0	0.0
5:00 PM	3.8	2.2	2.1	2.1	2.0	0.0



# Task-Based Motor Assessments

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
7:01 AM	4.0	3.5	2.5	2.4	2.2	0.0
7:02 AM	SINEMET (100mg)					
7:32 AM	3.4	3.3	1.7	1.4	1.0	0.0
8:01 AM	3.0	3.0	1.8	1.8	1.2	0.0
8:34 AM	2.9	2.8	1.3	1.2	1.0	0.0
9:00 AM	2.8	2.4	1.2	1.1	1.2	0.0
9:23 AM	2.8	2.6	1.0	1.0	1.0	0.0
10:00 AM	2.6	2.8	1.0	1.0	1.0	0.0
10:33 AM	3.2	3.3	1.5	1.9	1.5	0.0
11:01 AM	3.5	3.5	2.3	2.2	2.0	0.0
11:30 AM	3.7	3.8	2.0	2.0	1.8	0.0
12:00 PM	SINEMET (100mg)					
12:01 PM	3.3	3.8	2.6	2.7	2.0	0.0
12:32 PM	3.2	3.4	1.8	1.9	2.0	0.0
1:08 PM	2.6	3.1	2.0	1.4	1.8	0.0
1:28 PM	2.6	2.9	1.5	1.2	1.7	0.0
2:00 PM	2.7	2.7	1.3	1.0	1.5	0.0
2:32 PM	2.9	2.6	1.0	1.2	1.7	0.0
3:00 PM	3.0	2.9	1.1	1.5	1.3	0.0
3:29 PM	3.3	3.1	1.4	1.7	1.7	0.0
4:02 PM	3.8	3.6	1.6	1.8	1.8	0.0
4:30 PM	3.9	3.8	1.9	1.9	2.0	0.0
5:01 PM	3.9	3.9	2.5	2.4	2.0	0.0
5:15 PM	SINEMET (100mg)					
5:29 PM	3.5	3.6	2.1	2.2	2.0	0.0
6:02 PM	3.3	3.5	2.0	2.1	1.6	0.0
6:30 PM	3.0	2.9	1.9	2.0	1.5	0.0
7:00 PM	2.8	2.5	1.5	1.8	1.3	0.0
7:33 PM	2.6	2.6	1.2	1.5	1.1	0.0
8:04 PM	2.6	2.6	1.0	1.4	0.9	0.0
8:30 PM	2.9	2.8	1.2	1.5	1.1	0.0
9:02 PM	3.3	3.2	1.3	1.6	1.4	0.0
9:33 PM	3.5	3.6	1.6	1.8	1.8	0.0
10:00 PM	3.8	3.9	2.0	1.9	2.1	0.0
Mean	3.2	3.2	1.6	1.7	1.6	0.0
Fluctuation	0.4	0.5	0.5	0.4	0.4	0.0



  
 Increase dose  
 by 200mg,  
 Dose interval  
 unchanged

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
6:55 AM	3.9	3.4	2.6	2.5	2.3	0.0
6:57 AM	SINEMET (300mg)					
7:28 AM	2.5	3.0	1.7	1.4	1.0	0.0
7:59 AM	0.5	1.9	1.8	1.5	1.2	1.3
8:30 AM	0.3	0.9	0.3	0.5	1.0	2.9
9:05 AM	0.1	0.5	0.2	0.2	1.2	3.5
9:33 AM	0.3	0.4	0.0	0.0	1.0	3.8
10:02 AM	0.5	0.1	0.5	0.3	1.0	3.7
10:31 AM	1.5	2.0	1.0	0.5	1.5	2.9
10:58 AM	3.0	3.1	2.3	2.2	2.0	0.0
11:35 AM	3.5	3.4	2.0	2.0	1.8	0.0
11:50 PM	SINEMET (300mg)					
11:56 PM	1.1	2.7	2.3	2.2	2.0	0.0
12:30 PM	0.2	2.0	1.8	1.9	2.0	3.0
1:04 PM	0.1	1.4	2.0	1.4	1.8	3.3
1:38 PM	0.0	1.1	0.8	0.9	1.7	3.5
2:02 PM	0.0	1.0	0.6	1.0	1.5	3.6
2:30 PM	0.2	1.0	1.0	1.2	1.7	2.4
3:07 PM	0.4	0.7	1.1	1.5	1.3	1.1
3:33 PM	0.5	1.3	1.4	1.7	1.7	0.0
4:03 PM	2.6	1.5	1.6	1.8	1.8	0.0
4:28 PM	3.5	2.0	1.9	1.9	2.0	0.0
5:00 PM	3.8	2.2	2.1	2.1	2.0	0.0
5:05 PM	SINEMET (300mg)					
5:39 PM	3.5	2.2	2.1	2.2	2.0	0.0
6:03 PM	2.3	2.0	2.0	2.1	1.6	0.0
6:29 PM	1.7	1.3	1.9	2.0	1.5	0.5
7:05 PM	0.8	1.1	1.5	1.8	1.3	1.0
7:36 PM	0.6	0.8	1.2	1.5	1.1	2.3
8:01 PM	0.3	0.6	1.0	1.4	0.9	3.8
8:28 PM	0.2	1.0	1.2	1.5	1.1	3.7
9:00 PM	0.3	1.1	1.3	1.6	1.4	1.3
9:34 PM	0.3	2.0	1.6	1.8	1.8	0.5
9:59 PM	2.8	2.3	2.0	1.9	2.1	0.0
Mean	1.3	1.6	1.4	1.5	1.6	1.6
Fluctuation	1.3	0.9	0.7	0.6	0.4	1.5





  
 Decrease dose  
 by 100mg,  
 Decrease dose  
 interval by  
 2 hours

Time	Rest Tremor	Postural Tremor	Finger Taps Speed	Finger Taps Amplitude	Finger Taps Rhythm	Dyskinesia
7:00 AM	3.5	3.2	2.7	2.5	2.4	0.0
7:01 AM	SINEMET (200mg)					
7:31 AM	2.0	2.1	1.9	2.1	2.2	0.0
8:00 AM	0.6	0.7	0.3	0.5	1.0	0.0
8:33 AM	0.3	0.5	0.2	0.2	1.2	0.0
8:59 AM	0.2	0.2	0.0	0.0	1.0	0.0
9:22 AM	0.2	0.0	0.5	0.3	1.0	0.0
9:59 AM	1.1	1.5	1.0	0.5	1.5	0.0
10:32 AM	SINEMET (200mg)					
11:00 AM	1.2	1.3	1.5	1.4	1.5	0.0
11:29 AM	0.3	0.3	0.5	0.6	2.1	0.0
11:59 PM	0.2	0.2	0.3	0.3	1.0	0.0
12:00 PM	0.1	0.0	0.4	0.1	2.3	0.0
12:31 PM	0.2	0.6	0.6	0.1	2.1	0.0
1:07 PM	1.2	1.6	1.7	1.6	1.7	0.0
1:27 PM	SINEMET (200mg)					
1:59 PM	1.0	0.8	1.0	0.9	1.0	0.0
2:31 PM	0.3	0.7	0.3	0.8	0.9	0.0
2:59 PM	0.2	0.5	0.2	0.5	0.9	0.0
3:28 PM	0.0	0.3	0.2	0.8	0.9	0.0
4:01 PM	0.5	0.8	0.9	1.6	1.7	0.0
4:29 PM	1.3	1.7	1.6	2.1	2.1	0.0
5:00 PM	SINEMET (200mg)					
5:14 PM	1.0	1.5	1.0	0.9	1.0	0.0
5:28 PM	0.3	0.6	0.3	0.8	2.4	0.0
6:01 PM	0.2	0.3	0.2	0.5	2.0	0.0
6:29 PM	0.0	0.0	0.2	0.8	1.7	0.0
6:59 PM	0.5	0.2	0.9	1.6	1.2	0.0
7:32 PM	1.3	0.9	1.6	2.1	1.0	0.0
8:03 PM	SINEMET (200mg)					
8:29 PM	0.8	0.6	0.5	0.7	0.5	0.0
9:01 PM	0.0	0.2	0.2	1.1	0.9	0.0
9:32 PM	0.0	0.1	0.9	1.6	1.3	0.0
9:55 PM	0.5	0.6	1.9	2.0	1.9	0.0
Mean	0.7	0.8	0.8	1.0	1.5	0.0
Fluctuation	0.7	0.7	0.7	0.7	0.5	0.0

# Sensitivity of Data Versus Patient Burden



# Continuous Tremor Assessment








Published



D. A. Heldman, J. Jankovic, D. E. Vaillancourt, J. Prodoehl, R. J. Elble, and J. P. Giuffrida. Essential tremor quantification during activities of daily living. *Parkinsonism & Related Disorders*, 2011.

# Continuous Dyskinesia Assessment



Published




Christopher L. Pulliam, Michelle A. Burack, Dustin A. Heldman, Joseph P. Giuffrida and Thomas O. Mera. Motion Sensor Dyskinesia Assessment During Activities of Daily Living. *Journal of Parkinson's Disease* 2014.

# Wearable Sensors



## Mobile App



# Continuous Parkinson's Monitoring

## Summary Data

Total Wear Time: 9:52 HR

## Tremor Summary Data

	Time	Percent Wear Time
Total Time TremorDetect=0	2:46	28
Total Time TremorDetect=1	7:06	72
Time Rnd (TremorScore) = 0	2:46	28
Time Rnd (TremorScore) = 1	1:42	17.2
Time Rnd (TremorScore) = 2	5:24	54.7
Time Rnd (TremorScore) = 3	0:00	0
Time Rnd (TremorScore) = 4	0:00	0
Average (Tremor Score)	0.88	
Standard Dev (Tremor Score)	0.69	

## Dyskinesia Data Summary

	Time	Percent Wear Time
Total Time DysDetect=0	8:20	84.5
Total Time DysDetect=1	1:32	15.5
Time Rnd (DysProb) = 0	7:42	78
Time Rnd (DysProb) = .5	0:38	6.4
Time Rnd (DysProb) = 1	1:32	15.5


## Mobility Data Summary

	Time	Percent Wear Time
Total Time Rest	0:25	4.3
Total Time Active (Non-Gait)	2:14	22.7
Total Time Gait	7:12	73
Total Active Time	9:26	95.7
Wear Time Steps	549	
% Arm Swing During Gait	92.1	

## Subject Reported Diary


	Time	Percent Day	Percent Waking Day
Sleeping	9:30	39.6	
OFF	8:30	35.4	58.6
ON	1:30	6.3	10.3
ON with Non-Troublesome Dys	2:00	8.3	13.8
ON with Troublesome Dys	2:30	10.4	17.2

# Continuous Parkinson's Monitoring




# Patient Perspective

### The sensor was easy to put on





### The sensor is comfortable






# Deep Brain Stimulation: Outpatient Programming



# Objective Sensor



## DBS Programming Map





## Web Portal




Status	Start Date	Last Name	First Name	Last Modified
Pending Upload	04/06/2011	Doe	John	04/06/2011 7:54:29 AM
Archived Report		Smith	Jim	02/04/2011 3:19:46 PM
Archived Report		Smith	Jim	02/04/2011 3:19:40 PM
Archived Report	02/28/2012	Smith	Jim	10/07/2010 11:39:47 AM
Archived Report	10/07/2010	Doe	John	10/07/2010 11:36:08 AM
Archived Report		James	Georgia	10/07/2010 11:02:11 AM
Archived Report		Smith	Jim	10/07/2010 11:07:16 AM
Archived Report		Doe	John	10/07/2010 11:02:35 AM
Pending Upload	10/07/2010	Doe	John	10/07/2010 10:20:44 AM
Archived Report	10/09/2011	James	Georgia	10/07/2010 9:43:00 AM




# Closing The Clinical Workflow



# Rest Tremor DBS Tuning Maps



# Potential Solution for DBS Programming




## Can a Computerized Sensing System...

1. Find DBS Settings that Improve Motor Outcomes Compared to Clinicians?
2. Find DBS Settings that Provide Similar Motor Outcomes at Lower Amplitude?
3. Automatically Guide a Programming Session to Improve Motor Outcomes?


# Post Hoc Comparisons to Clinicians

## DBS Parameter Selection



# Post Hoc Comparisons to Clinicians


## Optimization Algorithms for Tremor & Bradykinesia





# Post Hoc Comparisons to Clinicians

## Optimization Algorithms for Tremor & Bradykinesia



# Real-Time Computer Guided Programming

## Algorithm Settings

Subject	Contact / Polarity	Amplitude	Pulse Width ( $\mu$ s)	Frequency (Hz)	Kinesia Score Off	Kinesia Score On After Functional Mapping	Percent Improvement
1	0-/C+	1.8 mA	90	130	0.5	0.4	14.5%
2	1-/C+	0.5 mA	90	130	0.9	0.5	47.9%
3	0-/C+	1.2 mA	90	130	1.8	1.5	13.7%
4	2-/C+	3.9 mA	90	130	2.8	2.0	29.6%
6	1-/C+	1.5 mA	90	130	1.5	0.9	38.1%
7	1-/C+	2.4 mA	90	130	2.8	0.5	82.7%
Average					<b>1.7</b>	<b>1.0</b>	<b>37.8%*</b>

\*p = 0.01

## Closing The Business Case

# Reimbursement



Reimbursement

Delivery Models



Reimbursement

Delivery Models

Business Models



Reimbursement

Delivery Models

Business Models

EHR Integration



Copyright © 2011 R.J. Romero. www.hipaacartoons.com

"All this talk about EMRs and EHRs is just a fad - like the Internet thing."

Closing The Patient Perspective



**I, Myself, Want to See...**

**Wearables are Important Because...**



**Wearables Roadmap  
For the Future?**

# Acknowledgements: Clinical Collaborators

Site	Location	Collaborator(s)	Research Area
Baylor College of Medicine	Houston, TX	Dr. Joseph Jankovic	Tremor Assessment, Telemedicine
Cleveland Clinic	Cleveland, OH	Dr. Hubert Fernandez;	Bradykinesia Assessment
Henry Ford Health System	Detroit, MI	Dr. Peter LeWitt	Quantitative PD Assessment, Neuroprotection
Kent State University	Kent, OH	Angie Ridgel, PhD	PD Exercise Therapy
Johns Hopkins University	Baltimore, MD	Dr. Zoltan Mari	Quantitative PD Assessment
University of Rochester	Rochester, NY	Dr. Ray Dorsey	Telemedicine
NIH NINDS	Bethesda, MD	Dr. Mark Hallett	tDCS for Parkinson's
Rush University	Chicago, IL	Dr. Christopher Goetz	Patient Home Evaluations, Telemedicine
Southern Illinois University School of Medicine	Springfield, IL	Dr. Rodger Elble	Tremor Assessment
Greenville Neuromodulation Center	Greenville, PA	Dr. Erwin Montgomery	DBS, Rigidity, Telemedicine
University of Cincinnati College of Medicine	Cincinnati, OH	Dr. Espay, Dr. Revilla, and Dr. Duker	Quantitative Assessments, Home Monitoring, Deep Brain Stimulation
University Hospitals Case Medical Center	Cleveland, OH	Dr. David Riley and Dr. Ben Walter	Tremor, Bradykinesia, Gait, Balance, and DBS
University of Florida	Gainesville, FL	David Vallaincourt, PhD	Tremor
University of Minnesota	Minneapolis, MN	Dr. Jerrold Vitek	Deep Brain Stimulation
University of Rochester	Rochester, NY	Dr. Michelle Burack	Dyskinesias
University of Florida	Gainesville, FL	Dr. Michael Okun	Patient Home Evaluations
Hospital Universitario de Burgos	Burgos, Spain	Dr. Esther Cubo	Telemedicine

# Acknowledgements: NIH SBIR Funding

National Institute of Neurological  
Disorders and Stroke

National Institute on Aging

National Institute on Minority Health  
and Health Disparities

R44NS065554

R43NS081902

R44AG034708

R43NS071882

R44AG044293

R43NS074627

R43NS052020

R43NS076052

R44AG033947

R44AG033520

R44MD004049

R44NS043816

# Questions?



Joseph P. Giuffrida, PhD  
President & Principal Investigator

[www.GLNeuroTech.com](http://www.GLNeuroTech.com)

[jgiuffrida@GLNeuroTech.com](mailto:jgiuffrida@GLNeuroTech.com)

216-619-5904